ArticleCellular oncology (Dordrecht, Netherlands)2026
CSRP2 modulates PDGFRA/PI3K/AKT signaling via PRC1 components in glioma.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeGlioblastoma (GBM) is the most common and aggressive primary brain tumor, characterized by poor prognosis and therapeutic resistance. Mesenchymal gliomas, in particular, exhibit more aggressive behavior and worse outcomes. This study investigates the role of CSRP2 in glioma progression and its epigenetic regulation of oncogenic pathways.
methodsWe analyzed TCGA, CGGA, and GEO datasets to identify genes enriched in mesenchymal gliomas and associated with poor prognosis. CSRP2 function was evaluated using CRISPR/Cas9 knockout in glioma cell lines and in xenograft models. Mechanism was examined by RNA-seq and promoter-focused CUT&Tag at the PDGFRA locus.
resultsCSRP2 is highly expressed in GBM, particularly in mesenchymal gliomas, and is associated with poor prognosis. Knockout of CSRP2 significantly inhibited glioma cell proliferation, migration, and invasion, and induced G2/M phase arrest. Transcriptomic analysis indicated that CSRP2 modulates tumor-associated gene programs, with PDGFRA emerging as a prominent target. CUT&Tag showed that CSRP2 co-occupies the PDGFRA promoter with the PRC1 components BMI1 and RNF2. CSRP2 knockout reduced BMI1 and RNF2 occupancy, decreased H3K27ac, and increased H2AK119ub1 at this promoter. These promoter-level changes were accompanied by lower PDGFRA transcription and attenuated PI3K/AKT signaling.
conclusionsOur data indicate that CSRP2 modulates glioma progression via PRC1-associated regulation at the PDGFRA promoter and downstream PDGFRA/PI3K/AKT signaling. CSRP2 may serve as a biomarker candidate. Therapeutic relevance remains to be established. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.